Skip to main navigation Skip to search Skip to main content

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02): American Society of Hematology, 61th Annual Meeting, scientific session

  • Heinz Ludwig
  • , Siegfried Sormann
  • , Niklas Zojer
  • , Johannes Andel
  • , Bernd L. Hartmann
  • , Christoph Tinchon
  • , Eberhard Gunsilius
  • , Klaus Podar
  • , Alexander Egle
  • , Wolfgang Willenbacher
  • , Ewald Wöll
  • , Reinhard Ruckser
  • , Boris Bozic
  • , Maria-Theresa Krauth
  • , Andreas Petzer
  • , Clemens A. Schmitt
  • , Sigrid Machherndl-Spandl
  • , Hermine Agis
  • , Bruno Paiva
  • , Richard Greil

Research output: Journal article (peer-reviewed) › Conference contribution to journal

Fingerprint

Dive into the research topics of 'Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02): American Society of Hematology, 61th Annual Meeting, scientific session'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Nursing and Health Professions